

AMENDMENTS TO THE CLAIMS

Claims 1-27 (Canceled)

28. (New) A transgenic mouse embryo whose genome comprises a homozygous disruption in an endogenous 5-HT-2B gene, wherein the transgenic mouse lacks production of functional 5-HT-2B protein and exhibits, relative to a wild-type mouse, a developmental abnormality comprising retarded growth, retarded development, arrested development or resorption.
29. (New) The transgenic mouse of claim 28, wherein the developmental abnormality occurs before embryonic day 8.5.
30. (New) A method of producing a transgenic mouse embryo comprising a disruption in an endogenous 5-HT-2B gene, the method comprising:
- (a) introducing a targeting construct capable of disrupting the endogenous 5-HT-2B gene into a mouse embryonic stem cell;
 - (b) introducing the mouse embryonic stem cell into a mouse blastocyst;
 - (c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein the pseudopregnant mouse gives birth to a chimeric mouse;
 - (d) breeding the chimeric mouse to produce the transgenic mouse comprising a heterozygous disruption in the endogenous 5-HT-2B gene; and
 - (e) breeding the transgenic mouse produced in step (d) to produce a transgenic mouse embryo comprising a homozygous disruption in the 5-HT-2B gene, wherein the transgenic mouse embryo lacks production of functional 5-HT-2B protein and exhibits, relative to a wild-type mouse, a developmental abnormality comprising retarded growth, retarded development, arrested development or resorption.
31. (New) The method of claim 30, wherein the developmental abnormality occurs before embryonic day 8.5.